Open-label study of the effect of combination quetiapine/lithium therapy on lithium pharmacokinetics and tolerability (Q44261941)

3

1 reference

1 December 2017

Daniel Carreon

4

1 reference

1 December 2017

Gustavo Alva

5

1 reference

1 December 2017

Amir H Kalali

6

1 reference

1 December 2017

Chiao Yeh

Lithium Treatment in Schizophrenia and Schizo-Affective Disorders

7

1 reference

1 December 2017

1 November 2002

1 reference

1 December 2017

Clinical Therapeutics

1 reference

1 December 2017

24

1 reference

1 December 2017

1809-1823

1 reference

1 December 2017

11

1 reference

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980081-9

7 January 2021

Neurotoxicity with combined administration of lithium and a neuroleptic

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980081-9

7 January 2021

Review of quetiapine and its clinical applications in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980081-9

7 January 2021

Selective antidopaminergic effects of S(+)N-n-propylnoraporphines in limbic versus extrapyramidal sites in rat brain: comparisons with typical and atypical antipsychotic agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980081-9

7 January 2021

Seroquel: electrophysiological profile of a potential atypical antipsychotic.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980081-9

7 January 2021

Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980081-9

7 January 2021

Seroquel: biochemical profile of a potential atypical antipsychotic.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980081-9

7 January 2021

ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980081-9

7 January 2021

ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980081-9

7 January 2021

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980081-9

7 January 2021

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980081-9

7 January 2021

Pharmacokinetic drug interactions with ACE inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980081-9

7 January 2021

Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980081-9

7 January 2021

Analysis and pharmacokinetics of quetiapine and two metabolites in human plasma using reversed-phase HPLC with ultraviolet and electrochemical detection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980081-9

7 January 2021

The effect of the combination of lithium and haloperidol on brain intermediary metabolism in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980081-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980081-9

1 reference

7 January 2021